This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Dividend Stocks That Want to Pay You More Money

Abbott Labs

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Diversified pharmaceutical firm Abbott Labs (ABT - Get Report), another of 2012's "Dividend Opportunity" stocks, is another name that hiked its payouts last week, ratcheting its dividend by 6.25% to 51 cents per share. That's a 3.62% yield at current levels.

While Abbott generates the majority of its sales though pharmaceuticals, the firm's exposure to medical devices and nutritional products makes the firm much more diversified than most of its peers. In a time where patent drop-offs are scaring investors away from big pharma more than ever before, Abbott's exposure to side businesses should look especially attractive.

That won't be the case for long, though -- Abbott is planning on splitting its pharmaceutical arm off from its health-care business. The move should squeeze some added returns out of the business at the risk of much more concentrated sector risk.

That said, the risks are a moot point for shareholders who own Abbott now; they will get shares of both companies.

On the other hand, current shareholders will also get to benefit from the value that's unlocked from the deal. In a market where valuations are under pressure, a sum-of-the-parts valuation is often less attractive than breaking businesses up. The move will boost margins at the pharmaceutical arm and make it more directly comparable with big pharma peers.

Ample balance sheet liquidity should keep dividends rolling for ABT shareholders.

In the fourth quarter, Fortress Investment Group initiated a new position in Abbott, which is also one of Ken Fisher's top holdings.

3 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ABT $38.10 -1.17%
ALL $65.28 -0.20%
CMCSA $60.89 -0.10%
PEG $46.64 1.19%
TJX $77.01 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs